Dianthus Therapeutics, Inc.
DNTH
Classement en actions
#3908
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Prix de l'action
$75.21
Dernière synchronisation: 2026-10-19
Capitalisation boursière
$4.21B
Changement (1 jour)
4.33%
Changement (1 an)
108.93%
Pays
US
Échange Dianthus Therapeutics, Inc. (DNTH)
Catégorie
Healthcare
Ratio P/B pour Dianthus Therapeutics, Inc. (DNTH)
Ratio P/B au October 2026 TTM : 3.57
Selon les derniers rapports financiers et le cours de l'action de Dianthus Therapeutics, Inc., le ratio cours/valeur comptable actuel (TTM) est 3.57. À la fin de 2023, le ratio P/B était de 0.32.
Historique du ratio P/B pour Dianthus Therapeutics, Inc. de 2016 à 2026
Ratio P/B à la fin de chaque année
| Année | Ratio P/B | Changez |
|---|---|---|
| 2026 (TTM) | 3.57 | 73.49% |
| 2024 | 2.06 | 549.15% |
| 2023 | 0.32 | -159.46% |
| 2022 | -0.53 | -137.87% |
| 2021 | 1.41 | -41.09% |
| 2020 | 2.39 | -39.79% |
| 2019 | 3.97 | 204.85% |
| 2018 | 1.30 | -87.23% |
| 2017 | 10.21 | -82.03% |
| 2016 | 56.80 | 0.00% |
Ratio P/B pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/B | Différence de Ratio P/B | Pays |
|---|---|---|---|
| 6.251 | 74.91% |
US
|
|
| 13.2547 | 270.87% |
US
|
|
| 4.208 | 17.74% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 72.99% |
NL
|
